G1T38: Experimental Treatment for Estrogen Receptor-Positive, HER2-negative (ER+, HER2-) Breast Cancer
Scientific rationale and therapeutic potential
G1T38 is a potent and selective oral CDK4/6 inhibitor designed to block the proliferation of breast-cancer cells and induce tumor-cell death when combined with a selective estrogen receptor degrader (SERD, such as Faslodex®). G1T38 has the potential to be best-in-class versus other oral CDK4/6 inhibitors.
Preclinical and clinical results (see: Publications)
- Preclinical data presented at the American Association for Cancer Research 2016 Annual Meeting demonstrated that G1T38 is more potent and has less toxicity than other CDK4/6 inhibitors in development.
- A recently completed Phase 1 trial in 75 healthy volunteers demonstrated that G1T38 was well tolerated with no grade 3/4 adverse events and no serious adverse events.
G1 is currently recruiting patients for a Phase 1b/2a trial of G1T38 in ER+, HER2- breast cancer
For additional information on the trials, please visit: G1CancerTrials.com